ChemoCentryx
CCXI
$51.99
Share price
0.00%
Change (1 day)
33.72%
Change (1 year)
Categories
Operating Margin for ChemoCentryx (CCXI)
Operating Margin as of May 2024 (TTM): -404.57%
According to ChemoCentryx's latest financial reports and stock price the company's current Operating Margin is -404.57%. At the end of 2021 the company had an Operating Margin of -404.58%.
Operating Margin history for ChemoCentryx from 2010 to 2022
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -404.58% | 394.21% |
| 2020 | -81.86% | -44.82% |
| 2019 | -148.36% | 73.13% |
| 2018 | -85.70% | -495.77% |
| 2017 | 21.65% | -106.2% |
| 2016 | -349.48% | |
| 2013 | -637.19% | -11.68% |
| 2012 | -721.48% | 5784.99% |
| 2011 | -12.26% | 38.4% |
| 2010 | -8.86% | -127.55% |
| 2009 | 32.15% | -141.23% |
| 2008 | -77.98% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 22.88% | -105.66% | 🇺🇸 USA |
 Pfizer PFE | 34.61% | -108.55% | 🇺🇸 USA |
 AbbVie ABBV | 18.65% | -104.61% | 🇺🇸 USA |
 Amgen AMGN | 34.59% | -108.55% | 🇺🇸 USA |
 Biogen BIIB | 31.30% | -107.74% | 🇺🇸 USA |
 Merck MRK | 27.73% | -106.85% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -104.76% | 🇺🇸 USA |
 GlaxoSmithKline GSK | 22.54% | -105.57% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -20.53% | -94.93% | 🇮🇱 Israel |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.